5-Amino-1MQ

5-Amino-1MQ is a small, membrane-permeable inhibitor of nicotinamide N-methyltransferase (NNMT) — an enzyme that gets massively overexpressed in the white adipose tissue and liver of obese, insulin-resistant, and aging humans. Shutting NNMT down rewires cellular energy metabolism through three linked pathways: NAD⁺ salvage, SAM/polyamine flux, and adipocyte lipid handling. That's the whole story behind the fat-loss, recomp, and muscle-quality effects the community is chasing.

NNMT Inhibition and the NAD⁺ Salvage Pathway#

NNMT's day job is methylating nicotinamide (vitamin B3) into 1-methylnicotinamide using S-adenosylmethionine (SAM) as the methyl donor. When NNMT is overexpressed, it acts as a drain on the NAD⁺ pool — nicotinamide that should be recycled back into NAD⁺ via NAMPT gets exported as 1-MNA instead. Block NNMT, and salvage flux rises, sirtuin (SIRT1/SIRT3) activity goes up, and mitochondrial oxidative capacity improves.

"Pharmacologic inhibition of NNMT elevates NAD⁺ levels and can synergize with precursor supplementation to support cellular NAD⁺ pools." — Conlon N, Ford D. Biochemical Pharmacology, 2022

This is the mechanistic basis for stacking 5-Amino-1MQ with NR or NMN: the precursors refill the pool, the NNMTi plugs the leak.

SAM Preservation and Thermogenic Polyamine Cycling#

Because NNMT consumes SAM, inhibiting it preserves the cellular methyl-donor pool and pushes flux into the polyamine pathway (ornithine decarboxylase, SSAT). The resulting futile polyamine cycle burns ATP and raises adipocyte oxygen consumption — energy expenditure goes up without appetite suppression or sympathetic stimulation.

"Knockdown of NNMT in adipose tissue and liver protects against diet-induced obesity by increasing cellular energy expenditure." — Kraus D. et al. Nature, 2014

Practically: this is why 5-Amino-1MQ is a partitioner, not a stimulant. No jitters, no appetite drop, no blood-pressure hit — the extra calories get burned at the adipocyte level.

Adipocyte Remodelling and Lipolysis#

NNMT is most dramatically overexpressed in white adipose tissue. Inhibition suppresses adipocyte differentiation in vitro and shrinks WAT depots in vivo — without reducing food intake. This is the core fat-loss mechanism and it's specific to adipose tissue rather than systemic catabolism.

"NNMT inhibitors produced significant body weight and white adipose tissue loss without reducing food intake in obese mice." — Neelakantan H. et al. Biochemical Pharmacology, 2018

"The upregulation of NNMT in adipose tissue is closely linked with obesity and insulin resistance, making NNMT inhibition a potential therapeutic target." — Liu JR. et al. Biomed Res Int, 2021

Expect this to bias fat loss toward visceral and stubborn lower-body subq depots — the tissues where NNMT overexpression is most pronounced in metabolically-impaired individuals.

Skeletal Muscle Quality and Exercise Mimicry#

This is the newer story and the reason the compound migrated from the longevity corner of the community into physique protocols. NNMT is also expressed in skeletal muscle, where its inhibition appears to mimic and amplify the adaptations normally driven by training — fiber cross-sectional area, grip strength, and intramyocellular lipid clearance all improve.

"NNMT inhibition alone improved grip strength and muscle fiber cross-sectional area, and combined with exercise yielded additive benefits on muscle function in aged mice." — Dimet-Wiley A. et al. Scientific Reports, 2024

The additive effect with training is the key finding: 5-Amino-1MQ isn't a replacement for lifting, it's a sensitizer. This is also why it pairs so cleanly with GLP-1 agonists — where the concern is lean-mass loss during aggressive kcal restriction, NNMT inhibition raises muscle NAD⁺ and appears to protect muscle function.

Why the Mechanism Matters Practically#

Every downstream effect users care about — slow steady fat loss, better kcal partitioning on a clean bulk, protection of muscle quality on a GLP-1 cut, stacking synergy with NR/NMN — falls out of the same root action: blocking one methyltransferase that's pathologically overexpressed in the exact tissues physique-focused users are trying to change. That's why the dosing works across such different use-cases at roughly the same 50–150 mg/day range.

Common (most users)#

The subjective side-effect profile is genuinely mild — this is one of the cleaner metabolic compounds in the community rotation. Most users report nothing at all for the first week or two.

• Mild GI upset / loose stools — usually in week 1. Take capsules with food (breakfast and a real lunch, not black coffee). Resolves on its own.
• Transient headache or fatigue — typically first 3–7 days as NAD⁺ flux shifts. Hydrate, add electrolytes, don't increase the dose until it clears.
• Insomnia if dosed late — the ~7-hour half-life means an afternoon dose still has you at meaningful plasma levels at bedtime. Don't dose past ~3 PM. Last dose at lunch or pre-workout, never with dinner.
• Mild flushing or warmth — occasional, benign, tied to the 1-MNA / NAD⁺ axis and polyamine flux. No action needed.
• Blunted appetite suppression expectations — not a side effect per se, but worth flagging: this compound does not suppress appetite the way a GLP-1 does. If you expected that, you'll overeat into your deficit. Structure the diet; don't rely on cravings to disappear.

Uncommon (dose-dependent or individual)#

Mostly shows up at the 150 mg/day ceiling or when stacked aggressively with methyl-consuming compounds (NR, NMN, high-dose creatine, TMG-deficient diets).

• Methylation imbalance symptoms (irritability, jitteriness, sleep disturbance) when stacked with NR/NMN — NNMT inhibition preserves SAM, and adding NAD⁺ precursors on top can shift the methylation economy. Fix: add TMG 500 mg/day as a methyl donor hedge, or run the two compounds in sequence rather than simultaneously.
• Mild LFT bumps on users who are also running oral AAS, high-dose nandrolone, or heavy alcohol intake. NNMT is expressed in liver, and while 5-Amino-1MQ is not hepatotoxic in rodents, the liver is working on multiple fronts in that scenario. Check ALT/AST at week 8. Back off if ALT climbs >2× baseline.
• Energy dips late afternoon if dosing is front-loaded and you're in a deep kcal deficit. Split the dose more evenly (3× 50 mg) rather than 2× 75 mg.
• Subjective "flat" feeling in weeks 10–12 — the plateau curve is real; efficacy decays after ~12 weeks. Don't push past 12; take 4+ weeks off.

Rare but serious#

No serious adverse events have been documented in humans, and preclinical toxicology is reassuring — genotoxicity panels (Ames, mammalian cell, mouse micronucleus) are all negative. The items below are theoretical concerns worth monitoring rather than documented signals.

• Significant LFT elevation on long-term use, particularly stacked with oral 17α-alkylated AAS. Stop if ALT/AST climb >3× baseline and don't restart until normalized.
• Paradoxical tumor-microenvironment concerns — NNMT is upregulated in many cancers and its inhibition slows tumor cell proliferation in vitro, but anyone with an active or recent malignancy should not freelance this compound. The mechanism is not benign in that context.
• Persistent insomnia or mood changes beyond week 2 — uncommon and usually resolve with dose timing adjustment, but if they persist despite moving the last dose to AM, discontinue.

"NNMT inhibitors produced significant body weight and white adipose tissue loss without reducing food intake in obese mice." — Neelakantan et al., Biochemical Pharmacology (2018)

Hard contraindications#

These are not negotiable:

• Pregnancy or attempting conception — zero reproductive toxicology data in any species. Do not run this if you or a partner could become pregnant during the cycle.
• Active malignancy — NNMT biology intersects with tumor metabolism in ways that are not fully mapped. Get oncology clearance before touching it.
• Severe hepatic impairment — documented Child-Pugh B/C, active hepatitis, or cirrhosis. The liver is a primary site of NNMT activity and the compound is cleared hepatically.
• Late-day dosing — functionally contraindicated. Dosing after mid-afternoon wrecks sleep quality in a meaningful fraction of users.

Gender, PCT, and fertility#

5-Amino-1MQ is non-hormonal, non-suppressive, and non-aromatizing. It does not touch the HPTA, so no PCT is required — run it, stop it, no restart protocol needed. Men's test/E2/LH/FSH are untouched by the mechanism.

Women run the same 50–100 mg/day range men do; contest-prep users have reported good results at 100 mg/day without dose adjustment. No virilization risk — this is not an androgen.

Fertility: no human data in either sex, which is why "attempting conception" sits in the hard-contraindication list. If you or your partner are actively trying to conceive, shelve it until after.